Home Value-based laboratory medicine: the time is now
Article Publicly Available

Value-based laboratory medicine: the time is now

  • Mario Plebani ORCID logo EMAIL logo
Published/Copyright: October 9, 2023

In the last few decades, laboratory medicine has undergone monumental changes and the landscape of clinical laboratories is still evolving over time. In particular, data on laboratory errors and associated diagnostic errors and risk for patient safety emphasize the need for a paradigmatic shift [12]: from a focus on volumes and efficiency to a patient-centered vision restoring the nature of laboratory services as an integral part of diagnostic and therapeutic pathways [3]. After focusing on internal indicators of analytical quality and efficiency, efforts are shifting toward indicators of total quality, clinical effectiveness and patient outcomes with an emphasis on the benefit created for patients by “value”, defined as the “outcomes achieved relative to costs” [4]. While this proposal is widely accepted as it is based on the seminal vision by Michael Porter that “health care is shifting focus from the volume of services delivered to the value created for patients, with ‘value’ defined as the outcomes achieved relative to the costs” [5], it is still poorly translated in practice. Progress is slow and halting, partly because outcomes measurements remain limited, not standardized and in laboratory medicine a well-defined link between laboratory quality and patient outcomes has proven to be elusive [6]: in fact, the “ultimate” measures of patient welfare, such as health status achieved or retained, as well as measures related to the process of recovery, and hospital discharge and readmission reflect the combined activities of clinicians, nurses, laboratory and radiology professionals, various other healthcare professionals as well as the patient. However, moving from volumes to value measured with reliable sets of outcomes represents a decisive step in accelerating value improvement in health care. Therefore, the paper by Tomaiuolo and Banfi published in this issue of the Journal should be welcome as it provides new and interesting data to support efforts to promote “value-based laboratory medicine” [7]. In their article, the authors underline that “the clinical laboratory could accelerate the transition from volume (output, understood as the mere numerical value obtained from the laboratory analysis) to value (outcome, understood as the laboratory data contextualized to the patient)…… aiming to produce the best outcomes possible in a real-life context (as opposed to clinical research settings),…… the laboratory specialists being part of a team responsible for clinical and operational decision-making” [7]. In the context of value-based laboratory medicine, a fundamental goal is to achieve not only efficiency but effectiveness, as the authors underline that “the effectiveness of clinical laboratory is achieved through understanding of the medical needs and delivering timely and high-quality tests. The role of clinical laboratories is closely linked to the increase in value; therefore, the main objective of the clinical laboratory professionals is to enhance the value of laboratory testing, optimizing their correct use both in the test selection request phase and in the reporting phase” [7]. Another fundamental step in promoting value-based laboratory medicine is to assure comparability of test results as the authors highlight that “the accountability and credibility of the clinical laboratory in low-volume vs. high-value settings are linked to total testing process harmonization”. First and foremost, there is the need to stimulate cooperation with in vitro diagnostic companies to achieve better analytical standardization for an increasing number of measurands. However, as mentioned by the authors, these efforts should not be limited to increase the comparability of analytical results, but to provide harmonization in all steps of the testing process, including “homogenization of reference values” and the evaluation of cost-effectiveness in this challenging regulatory framework. In a challenging scenario for all healthcare systems, the promotion of value-based laboratory medicine is a contribution not only to the sustainability but to the increasing need for measuring clinical and economical outcomes. If value is defined by the ratio between the outcomes and related costs, clinical laboratories have to promote improved outcomes (clinical effectiveness) while decreasing costs (efficiency). In other words, efforts based only on increasing volumes and economy of scales are totally inappropriate if the ultimate goal is to achieve better and higher quality of care. Combined efforts are needed to improve clinical outcomes while reducing costs, taking into consideration that the laboratory information is increasingly important but only in the right clinical context. Clinical laboratories have been pioneers in introducing process measures (internal quality control, external quality assurance and the model of quality indicators) to improve accuracy and reliability of laboratory results [8], and now they should play a key role in promoting value-based laboratory medicine to assure more effective, safe and patient-centered clinical diagnostic and therapeutic pathways.


Corresponding author: Mario Plebani, Honorary Professor of Clinical Biochemistry and Clinical Molecular Biology, University of Padova, Padova, Italy; and Adjunct Professor, Department of Pathology, University of Texas-Medical Branch, Galveston, TX, USA, E-mail:

References

1. Plebani, M. The detection and prevention of errors in laboratory medicine. Ann Clin Biochem 2010;47:101–10. https://doi.org/10.1258/acb.2009.009222.Search in Google Scholar PubMed

2. Plebani, M. Laboratory-associated and diagnostic errors: a neglected link. Diagnosis (Berl) 2014;1:89–94. https://doi.org/10.1515/dx-2013-0030.Search in Google Scholar PubMed

3. Plebani, M. Clinical laboratory: bigger is not always better. Diagnosis (Berl) 2018;5:41–6. https://doi.org/10.1515/dx-2018-0019.Search in Google Scholar PubMed

4. Plebani, M. Quality and future of clinical laboratories: the Vico’s whole cyclical theory of the recurring cycles. Clin Chem Lab Med 2018;56:901–8. https://doi.org/10.1515/cclm-2018-0009.Search in Google Scholar PubMed

5. Porter, ME. What is value in health care? N Engl J Med 2010;363:2477–81. https://doi.org/10.1056/nejmp1011024.Search in Google Scholar

6. Epner, PL. Appraising laboratory quality and value: what’s missing? Clin Biochem 2017;50:622–4. https://doi.org/10.1016/j.clinbiochem.2017.04.013.Search in Google Scholar PubMed

7. Tomaiuolo, R, Banfi, G. From volume to value: a watershed moment for the clinical laboratory. Clin Chem Lab Med 2024;62:593–6. https://doi.org/10.1515/cclm-2023-0870.Search in Google Scholar PubMed

8. Sciacovelli, L, Padoan, A, Aita, A, Basso, D, Plebani, M. Quality indicators in laboratory medicine: state-of-the-art, quality specifications and future strategies. Clin Chem Lab Med 2023;61:688–95. https://doi.org/10.1515/cclm-2022-1143.Search in Google Scholar PubMed

Published Online: 2023-10-09
Published in Print: 2024-03-25

© 2023 Walter de Gruyter GmbH, Berlin/Boston

Articles in the same Issue

  1. Frontmatter
  2. Editorial
  3. Value-based laboratory medicine: the time is now
  4. Review
  5. Cardiovascular risk evaluation in pregnancy: focus on cardiac specific biomarkers
  6. Opinion Papers
  7. From volume to value: a watershed moment for the clinical laboratory
  8. APS calculator: a data-driven tool for setting outcome-based analytical performance specifications for measurement uncertainty using specific clinical requirements and population data
  9. Guidelines and Recommendations
  10. Analytical interference of intravascular contrast agents with clinical laboratory tests: a joint guideline by the ESUR Contrast Media Safety Committee and the Preanalytical Phase Working Group of the EFLM Science Committee
  11. Genetics and Molecular Diagnostics
  12. Specifications of qPCR based epigenetic immune cell quantification
  13. General Clinical Chemistry and Laboratory Medicine
  14. An appraisal of the practice of duplicate testing for the detection of irregular analytical errors
  15. Machine learning-based nonlinear regression-adjusted real-time quality control modeling: a multi-center study
  16. The effect of ratios upon improving patient-based real-time quality control (PBRTQC) performance
  17. Diagnostic sample transport via pneumatic tube systems: data logger and their algorithms are sensitive to transport effects
  18. Ambulatory human chorionic gonadotrophin (hCG) testing: a verification of two hCG point of care devices
  19. Monitoring patients with celiac disease on gluten free diet: different outcomes comparing three tissue transglutaminase IgA assays
  20. Verification, implementation and harmonization of automated chemiluminescent immunoassays for MPO- and PR3-ANCA detection
  21. Performance evaluation of a novel platelet count parameter, hybrid platelet count, on the BC-780 automated hematology analyzer
  22. Reference Values and Biological Variations
  23. Pediatric reference intervals for serum neurofilament light and glial fibrillary acidic protein using the Canadian Laboratory Initiative on Pediatric Reference Intervals (CALIPER) cohort
  24. Biological variation of serum neopterin concentrations in apparently healthy individuals
  25. Short-term biological variation of serum tryptase
  26. Cancer Diagnostics
  27. Quantification of the lung cancer tumor marker CYFRA 21-1 using protein precipitation, immunoaffinity bottom-up LC-MS/MS
  28. Cardiovascular Diseases
  29. Prognostic significance of chronic myocardial injury diagnosed by three different cardiac troponin assays in patients admitted with suspected acute coronary syndrome
  30. Deep learning-based NT-proBNP prediction from the ECG for risk assessment in the community
  31. Diabetes
  32. Innovations in HbA1c analysis: finding the balance between speed and accuracy. An investigation of a potential new Secondary Reference Measurement Procedure for the IFCC
  33. Precise glucose measurement in sodium fluoride-citrate plasma affects estimates of prevalence in diabetes and prediabetes
  34. Infectious Diseases
  35. Urinary phenotyping of SARS-CoV-2 infection connects clinical diagnostics with metabolomics and uncovers impaired NAD+ pathway and SIRT1 activation
  36. Letters to the Editor
  37. Analytical performance specifications for measurement uncertainty in therapeutic monitoring of immunosuppressive drugs
  38. Capillary blood collection tubes containing serum separator gel result in lower measurements of oestradiol and total testosterone
  39. Re.: Louise Guillaume et al. Biological variation of CA 15-3, CA 125 and HE 4 on lithium heparinate plasma in apparently healthy Caucasian volunteers. Clin Chem Lab Med 2023;61(7):1319–1326; https://doi.org/10.1515/cclm-2022-0966
  40. A comparison of cannabidiol (CBD) concentrations in venous vs. fingertip-capillary blood
  41. Identification of sulfamethoxazole’s residues in sulfamethoxazole induced kidney stones by mass spectrometry
  42. Impact of different preservation methods on urinary red blood cell counts
  43. Diagnosis of IRAK-4-deficiency by flow cytometric measurement of IκB-α degradation
Downloaded on 8.10.2025 from https://www.degruyterbrill.com/document/doi/10.1515/cclm-2023-1095/html
Scroll to top button